Ipsen to acquire ImCheck Therapeutics to strengthen oncology pipeline

The acquisition centers on ImCheck’s lead Phase I/II program, ICT01, a first-in-class monoclonal antibody targeting BTN3A

Novo Nordisk to acquire Akero Therapeutics for $5.2 billion

Acquisition expands Novo Nordisk’s leadership in obesity-related comorbidities and metabolic diseases

Integris Medtech files DRHP with SEBI for IPO

The company plans to use the funds raised from the net proceeds to repay or prepay certain loans

Briefs: Shilpa Medicare and Medico Remedies

Medico Remedies receives order worth US$ 1,781,000

Merck completes acquisition of Verona Pharma

Through this acquisition Merck has added Ohtuvayre (ensifentrine) to its growing cardio-pulmonary pipeline and portfolio

Genmab to acquire Merus for $8 billion

Proposed acquisition adds petosemtamab, a late-stage asset with two Breakthrough Therapy Designations, to Genmab’s portfolio

AstraZeneca to harmonise its listing structure across LSE, STO and NYSE

Harmonisation of listing structure requires a direct listing of AstraZeneca shares on the NYSE in place of existing US ADRs

NATCO Pharma updates on acquisition of Adcock Ingram

Briefs: Torrent Pharmaceuticals and Hemant Surgical Industries

Hemant Surgical Industries receives order

Novartis to acquire Tourmaline Bio for $1.4 billion

Tourmaline Bio is a clinical-stage biopharmaceutical company developing pacibekitug, an anti-IL-6 mAb, as a treatment option for atherosclerotic cardiovascular disease